Compare Ono Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 12.49%
2
Company has very low debt and has enough cash to service the debt requirements
3
With a growth in Net Profit of 93.19%, the company declared Outstanding results in Dec 25
4
With ROE of 6.41%, it has a very attractive valuation with a 0.97 Price to Book Value
5
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,127,295 Million (Large Cap)
15.00
NA
0.00%
-0.07
6.01%
1.40
Revenue and Profits:
Net Sales:
139,900 Million
(Quarterly Results - Dec 2025)
Net Profit:
28,889 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.77%
0%
9.77%
6 Months
38.53%
0%
38.53%
1 Year
42.92%
0%
42.92%
2 Years
-5.39%
0%
-5.39%
3 Years
-12.51%
0%
-12.51%
4 Years
-23.4%
0%
-23.4%
5 Years
-16.54%
0%
-16.54%
Ono Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.73%
EBIT Growth (5y)
-4.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.57
Tax Ratio
15.48%
Dividend Payout Ratio
75.08%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
20.45%
ROE (avg)
12.49%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.97
EV to EBIT
10.81
EV to EBITDA
7.59
EV to Capital Employed
0.96
EV to Sales
1.41
PEG Ratio
NA
Dividend Yield
0.03%
ROCE (Latest)
8.91%
ROE (Latest)
6.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
139,900.00
134,223.00
4.23%
Operating Profit (PBDIT) excl Other Income
47,551.00
23,973.00
98.35%
Interest
408.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
28,889.00
14,886.00
94.07%
Operating Profit Margin (Excl OI)
271.30%
110.30%
16.10%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 4.23% vs 2.31% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 94.07% vs -58.75% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
486,871.00
502,672.00
-3.14%
Operating Profit (PBDIT) excl Other Income
90,278.00
181,701.00
-50.32%
Interest
1,635.00
105.00
1,457.14%
Exceptional Items
-1,645.00
-137.00
-1,100.73%
Consolidate Net Profit
50,166.00
128,040.00
-60.82%
Operating Profit Margin (Excl OI)
130.20%
325.40%
-19.52%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -3.14% vs 12.41% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -60.82% vs 13.40% in Mar 2024
About Ono Pharmaceutical Co., Ltd. 
Ono Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






